INTRODUCTION
Radiation therapy (RT) is a key component in the treatment of a majority of cancers of the head and neck. Although head and neck cancers (HNCs) associated with smoking and alcohol are in the decline, the incidence of oropharyngeal carcinoma is increasing. 1, 2 This trend is largely explained by the epidemic of human papillomavirus (HPV) infection, which is expected to cause even greater increases in the rates of HNC in the coming decades. 3, 4 These patients are younger, with greater life expectancies in which to experience long-term toxicity. Patients who receive RT for HNC often have significant acute toxicity, including mucositis and dysphagia, which can lead to malnutrition and dehydration, as well as a risk for chronic toxicity, such as esophageal stricture, dysphagia, and aspiration.
During the course of RT, patients who develop significant side effects and are at risk for malnutrition are typically referred for placement of a feeding tube. The feeding tube provides a portal for nutrition and medication administration that bypasses the areas affected by the local symptoms, including dysphagia, odynophagia, dysgeusia, or severe xerostomia; it is anticipated that a feeding tube can prevent malnutrition, dehydration, and treatment breaks. There is significant controversy about the optimal timing of feeding tube placement during treatment, with some studies favoring prophylactic placement [5] [6] [7] [8] [9] [10] [11] [12] and others indicating placement only as needed. [13] [14] [15] The argument against prophylactic placement arises in concerns about long-term feeding tube dependence in patients who receive upfront placement. 14 Regardless of the approach to the timing of feeding tube placement, previous studies suggest that the majority of patients who receive RT for locoregionally advanced HNC (range, 60%-70%) will require a feeding tube at some point during their course of therapy. 10, [16] [17] [18] Although the optimal strategy varies by center and practitioner, the impact of modern radiation techniques, namely, intensity-modulated RT (IMRT), on the need for feeding tube placement has not been rigorously evaluated. IMRT was developed with the goal of sparing normal tissues, namely, the parotid glands, while delivering curative dose to the tumor targets. IMRT has been widely adopted for the treatment of HNC. 19, 20 Previous studies have demonstrated improved dose-volume parameters for key normal structures, improved quality of life, better xerostomia scores, and improved cause-specific survival for patients who receive IMRT. [21] [22] [23] [24] Although patients who receive IMRT have been included in previous studies examining feeding tube use, most reports have not addressed the relation between IMRT and the placement and duration of feeding tube use. In theory, IMRT may provide a benefit with regard to swallowing, because it reduces high radiation doses to the pharyngeal constrictors (superior, middle, and inferior), cricopharyngeus muscle, esophageal inlet, and glottic structures (supraglottis and glottis) while still providing adequate doses to the target structures. 25, 26 The objectives of this study were to analyze the rates and duration of feeding tube use in patients who received both definitive and adjuvant RT for HNC using a large, population-based registry and to assess the impact of radiation technique (IMRT vs 3-dimensional RT [3DRT]).
MATERIALS AND METHODS

Data Source
The Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database was queried to identify a cohort of patients with HNC and to measure the outcomes of interest. The linked SEER program, which is a National Cancer Institute-supported database, includes tumor registries in 17 areas (Greater California, San Francisco-Oakland, Los Angeles, San Jose, Connecticut, Detroit, Seattle-Puget Sound, Atlanta-Rural Georgia, Greater Georgia, Iowa, Louisiana, New Mexico, Utah, Hawaii, Kentucky, Louisiana, and New Jersey), comprising more than 1.5 million cancer cases in the United States. 27 These data are linked to Medicare claims files by encrypted patient identifiers. Medicare provides payments for hospital, physician, and outpatient medical services for 97% of US citizens aged 65 years. 28, 29 Diagnoses and procedures for each patient were identified using the Patient Entitlement and Diagnosis Summary File as well as all available Medicare claims. All data were de-identified, and The University of Texas MD Anderson Cancer Center's Institutional Review Board Exempted this study.
Cohort Identification
We queried the database for patients who were diagnosed with HNC between 1999 and 2011, as defined by SEER and International Classification of Diseases ninth revision (ICD-9) codes, who received RT, including both definitive and adjuvant RT, and who had claims data through (20090); other oral cavity and pharynx (20100); nose, nasal cavity, and middle ear (22010); and larynx (22020). For patients who had tumor subsites that could represent multiple categories, we used a local treatment approach to determine anatomic location. For example, primary tumors of the tongue in patients who underwent surgery and received postoperative RT as primary treatment were classified as tumors of the oral cavity, whereas tumors in patients who received definitive RT were classified as tumors of the oropharynx. For inclusion, the tumor had to be pathologically confirmed, not diagnosed at death or autopsy; a stage had to be indicated; there could be no evidence of distant disease; and it must have been treated with IMRT or conventional 3DRT. Tumors that had been treated using 2D techniques were excluded. Patients who had stage I and II laryngeal cancer were excluded, because IMRT was rarely used in this group. Those who had salivary gland carcinomas also excluded because of the low rate of feeding tube use in this group. Patients were included only if they began definitive RT within 4 months or adjuvant RT within 6 months of diagnosis. The algorithm for the development of this cohort is provided in Table 1 .
Outcome Identification
The primary outcomes analyzed in this study were the placement, use, and duration of a feeding tube. Original Article B4034-B4036, B4081-B4088, B4100, B4102-B4104, and B4149-B4162) were used as the date of feeding tube initiation and was subsequently correlated to the timing of the start of RT. In general, codes for removal of a feeding tube are not frequently used (ICD-9 codes 97.51 and 97.52), because this is commonly performed during a routine office visit. Hence, the date of last claims for feeding tube supplies was used as a surrogate for removal and as the end date for feeding tube use. For patients who had used a feeding tube, the dates of both placement and removal were required for inclusion. The duration was calculated relative to the insertion date of the feeding tube. In addition, patients who had feeding tubes removed before the start of RT (n 5 39) were excluded along with those who had a second cancer diagnosis after their HNC was diagnosed (hence, excluding those with recurrent disease). Dobhoff tubes or nasogastric tubes were not captured in this analysis.
Definition of Explanatory Variables
To ascertain the impact of potential demographic and clinic variables, we analyzed the impact of age at diagnosis, ethnicity, Charlson comorbidity index, [30] [31] [32] [33] tumor site, SEER tumor stage, type of RT, receipt of surgery and chemotherapy, and year of treatment on the placement and duration of feeding tubes. To analyze the impact of RT technique, specific radiation treatment characteristics were identified from Medicare claims data through the ICD-9 procedure codes and CPT codes for RT planning and delivery. Patients were categorized as having received IMRT if there were any IMRT delivery or planning CPT codes (77418, 77301, GO174-IMRT, GO178-IMRT). Patients who did not have an IMRT planning or delivery code as part of their RT claims were categorized as having received 3DRT techniques if they had non-IMRT delivery codes as well as an accompanying planning code (77261, 77262, 77263). Patients who did not have a planning code were categorized as having received 2DRT and were excluded from the analysis (n 5 129). In addition to RT delivery, we identified receipt of surgery and chemotherapy using the claims codes for these modalities as part of primary management for a patient's disease at the time of diagnosis.
Statistical Analysis
Statistical analyses were conducted using SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC). The unadjusted associations of each potential explanatory variable with the outcomes of feeding tube use were assessed using the chi-square test, and the duration of feeding tube use was assessed using the Kruskal-Wallis test. We conducted multivariable modeling using zero-inflated negative binomial regression analysis. This model simultaneously estimates the likelihood of NOT having a feeding tube (zero-inflated binomial regression model) and the expected days of feeding tube (zero-inflated negative binomial regression model) use.
RESULTS
Study Cohort Characteristics
We identified 2993 patients who met our criteria for inclusion. The median follow-up for all patients was 47 months, and the median follow-up for all living patients was 67 months. Table 2 summarizes the demographic and treatment characteristics of the entire cohort and for the subsets of patients who underwent surgery and RT versus definitive RT. Of the entire cohort, 1574 patients (52.6%) received IMRT (median follow-up, 45 months), and 1419 (47.4%) received 3DRT (median follow-up, 51 months). Of the entire cohort, 1110 patients (37.1%) received surgery and adjuvant RT, and 1883 (62.9%) received definitive RT.
Impact of Clinical Characteristics on Feeding Tube Use for the Entire Cohort
In total, 1629 of 2993 patients (54.4%) had a feeding tube placed after their diagnosis of HNC. Several variables were correlated with higher rates of placement of a feeding tube on univariate analysis, including age (ages 70-74 years > 66-69 years > 75-80 years; P 5 .0311), sex (men > women; P 5 .0032), ethnicity (black nonHispanic; P 5 .003), tumor site (oropharynx > hypopharynx > larynx > nasopharynx > oral cavity > nose/nasal cavity/middle ear; P < .0001), RT regimen (definitive > adjuvant; P < .0001), receipt of chemotherapy (concurrent > induction > none; P < .0001), SEER tumor stage (regional > localized; P < .0001), and receipt of IMRT (IMRT > 3DRT; P < .0001). The impact of clinical variables on feeding tube use is in evaluated Table 3 . Very few feeding tubes were placed in patients who had sinonasal cancers.
On multivariable analysis with zero-inflated binomial regression analysis, which models the odds that a feeding tube was NOT placed and included the impact of year of diagnosis, patients who received IMRT had similar rates of feeding tube placement as those who received 3DRT (Table 4 ) (odds ratio [OR], 1.10; P 5 .35). Patients of black non-Hispanic ethnicity, those ages 70 to 74 years, those who had cancers at certain sites and regional disease, and those who received concurrent chemotherapy were more likely to have used a feeding tube (Table 4) .
Impact of Clinical Characteristics on Feeding Tube Duration for the Entire Cohort
Of the 1629 patients who used a feeding tube in the entire cohort, the median duration with a feeding tube in place was 277 days (interquartile range, 123-640 days). Despite similar tendencies in placement of feeding tubes between Abbreviations: 3DRT, 3-dimensional radiation therapy; IMRT, intensity-modulated radiation therapy; RT, radiation therapy.
Original Article The NB model estimates the expected counted days with a feeding tube. Exp(Est.) is the ratio of expected days compared with the reference value.
Original Article IMRT and 3DRT on multivariable analysis, patients who received IMRT had a statistically significant decrease in the median duration compared with those who received 3DRT (234 vs 335 days, respectively; P < .0001). On zero-inflated negative binomial analysis (a multivariable method of modeling the duration of feeding tube placement in days), patients who received 3DRT had feeding tubes in place 1.18 times longer than those who received IMRT (P 5 .03) ( Table 4 ). Evaluating the "survival" of the feeding tubes in the 1629 patients who received them, Kaplan-Meier analysis indicated that patients who received 3DRT consistently had increased rates of feeding tubes in place compared with those who received IMRT (Fig. 1A) .
Impact of Surgery on Feeding Tube Placement and Duration of Use
Because patients who undergo surgery along with receiving adjuvant RT may have different feeding tube needs compared with those who receive definitive RT, we evaluated the role of surgery in both endpoints (placement of feeding tubes and the duration of use). To do this, the entire cohort was split into 2 groups: those who received treatment with primary surgery and adjuvant RT (n 5 1110 patients) and those who received treatment with definitive RT (n 5 1883 patients).
Patients Who Underwent Surgery and Received Adjuvant RT
Of the 1110 patients in the surgery and adjuvant RT group, 523 (47.1%) had a feeding tube placed after their diagnosis of HNC. The impact of clinical variables on feeding tube use is detailed in Table 3 . On multivariable analysis with zero-inflated binomial regression analysis modeling the odds that a feeding tube was NOT placed, including the impact of year of diagnosis, patients who received IMRT had similar rates of feeding tube placement compared with those who received 3DRT (OR, 1.09; P 5 .63) ( Table 4) . Furthermore, there was no statistically significant difference in the median duration of feeding tube placement between patients who received IMRT and those who received 3DRT (222 vs 282 days, respectively). Zero-inflated negative binomial analysis modeling the duration of feeding tube placement in days indicated that there was no statistically significant difference in feeding tube duration between patients in the surgery and 3DRT group and those in the surgery and IMRT group (OR, 0.90; P 5 .47) (Table 4). The use of feeding tubes among patients in the surgery and adjuvant RT group is illustrated in Figure 1B . 
Patients Who Received Definitive RT
Of the 1883 patients who received definitive RT, 1106 (58.7%) had a feeding tube placed after their diagnosis of HNC. The impact of clinical variables on feeding tube use is detailed in Table 3 .
On multivariable analysis with zero-inflated binomial regression analysis modeling the odds that a feeding tube was NOT placed and including the impact of year of diagnosis, patients who received IMRT and those who received 3DRT had similar rates of feeding tube placement (OR, 1.11; P 5 .47) ( Table 4 ). On zero-inflated negative binomial analysis modeling the duration of feeding tube placement in days, patients who received 3DRT had feeding tubes in place 1.35 times longer than those who received IMRT (P < .01) ( Table 4) . The presence of feeding tubes in place for patients who received definitive RT is shown in Figure 1C .
DISCUSSION
In this population-based analysis, the data suggest that patients who receive definitive IMRT have similar rates of feeding tube placement, but a shorter duration of use, compared with those who receive 3DRT. In fact, even 12 and 24 months after RT, a greater proportion of patients who received non-IMRT treatment had not recovered to the extent that a feeding tube could be removed (Fig. 1) ; therefore, the short-term need for a feeding tube translates into long-term debility. These data suggest that IMRT has a significant benefit to patients in the return of functional swallowing for those who receive definitive RT; this finding is not demonstrated in patients who undergo surgery followed by adjuvant RT, in which case there are no statistically significant differences between IMRT and 3DRT.
Despite multiple published reports documenting feeding tube rates in patients with HNC, to date, there has been little analysis of the impact of IMRT. IMRT has been used for HNC since 1999, and the rates of use have grown rapidly. 19, 20 Three prior population-based analyses of feeding tube rates among patients who were treated for HNC failed to explicitly discuss the impact of IMRT. Locher and colleagues published 2 analyses of the SEERMedicare database in patients who were treated from 2000 through 2005. 34, 35 In the first analysis, the authors note a 35.1% rate of gastrostomy tube placement, with 16.9% placed prophylactically 35 ; the study did not assess the impact of IMRT or the duration of feeding tube use. Overall, the rates published in their analysis are significantly less than those observed in our current analysis; this is likely because of higher rates of feeding tube placement in later years, which may reflect the increasing use of prophylactic placement. The impact of prophylactic placement is beyond the scope of this discussion; however, there is a notable correlation between time and increasing use of both IMRT and prophylactic placement. In a second publication, Locher and colleagues analyzed factors that contribute to feeding tube placement in patients were treated from 2000 through 2005; they also did not assess the impact of IMRT. 34 They noted that patients who had laryngeal and oropharyngeal cancers had increased rates of prophylactic tube placement; given the significant increase in the rates of oropharyngeal cancer over the last decade, this finding is also consistent with the increased rates observed in the current analysis. The third populationbased analysis evaluated the outcomes of patients who were treated at the British Columbia Cancer Agency with prophylactic versus reactive feeding tube placement. 36 Those investigators reported that 41% of patients who received treatment at Center A (which generally used a reactive approach) and 47% of those who received treatment at Center B (which generally used a prophylactic approach) had received IMRT; there were no differences in overall survival or weight loss between the 2 centers. The impact of IMRT was not specifically discussed with regard to outcomes.
Several retrospective series have discussed the impact of RT technique on feeding tube placement and duration of use. Bhayani and colleagues reviewed 474 patients with oropharyngeal cancer, and 93% were treated with IMRT. 16 Overall, 62% of patients received feeding tubes. At 1 year, only 9% of patients remained dependent on enteral feeding. Strom and colleagues reported on 297 patients with oropharyngeal cancer who received concurrent chemoradiation with IMRT; the majority of patients received prophylactic feeding tubes. 37 Of the 128 patients (43.1%) who did not receive a prophylactic feeding tube, 11.7% required a reactive feeding tube for a median duration of 3.3 months (100.4 days). Naik and colleagues reviewed 147 patients with oropharynx cancer (130 HPVpositive) to understand the impact of HPV itself on swallowing outcomes. 38 Those authors noted that patients who had HPV-positive cancers had a statistically significant decrease in feeding tube dependence (4% vs 18%; P 5 .02). Hence, they hypothesize that improvements in swallowing outcomes may be caused not only by improved techniques but also by changing epidemiology.
Similar retrospective studies have investigated swallowing function after RT for hypopharyngeal cancers. Bhayani and colleagues reviewed the placement of feeding tubes in a series of 43 patients with hypopharyngeal
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Cancer cancer, 17 of whom 69% received IMRT. Overall, 69.8% of patients received feeding tubes. At 1 year, 25.6% of patients remained dependent on enteral feeding, and this dropped to 3.4% at 2 years. The median duration was 23.8 weeks (167 days). Mok and colleagues evaluated 181 patients with hypopharyngeal cancer, including 90 who received 3DRT and 91 who received IMRT. 39 In that evaluation, prophylactic feeding tubes were recommended for all patients who received chemoradiation and accelerated fractionation, and more patients who received IMRT had feeding tubes because of prophylactic placement. At 3 years, the IMRT group had higher locoregional control but similar rates of overall survival and feeding tube dependence (19% vs 18%). This similar long-term feeding tube dependence may be caused by differences in placement practices.
Overall, the current population-level analysis provides insight into the actual benefits of IMRT, one of our most widely used and resource-intensive technologies in radiation oncology, for patients who receive definitive RT. IMRT was largely adopted because of the ability to spare the parotid glands and improve xerostomia; this has been demonstrated in randomized trials. However, the relative impact of IMRT on swallowing function has not truly been assessed. The ability of IMRT to selectively allocate dose and spare normal tissues may allow for improved swallowing through protection of the pharyngeal constrictors, glottic structures, and esophageal inlet or indirectly through improved salivary function that protects the upper aerodigestive mucosa. In this study, we demonstrate that patients who receive IMRT typically have similar rates of feeding tube placement, but those who receive definitive IMRT and also use feeding tubes are more likely to recover swallowing function sufficient to stop using their feeding tube more quickly than those who receive 3DRT. In fact, even 2 years after treatment, the patients who received 3DRT had not yet returned to the same level of functionality as those who received IMRT. This may be the most compelling argument supporting the use of IMRT; those patients have improved swallowing rehabilitation and have reduced need for long-term feeding tube compared with those who received 3DRT. Given the relative good health and younger age of an ever-increasing number of patients with HPV-associated HNC, the reduction in toxicity and optimization of function in survivorship is paramount. These data suggest that IMRT helps achieve these goals. Although IMRT has become a standard of care in the past decade, its unintended consequences to other normal tissues (because of increased lowdose bath) have not been evaluated. Our current data further support the finding IMRT has benefits in terms of normal tissue toxicity above and beyond xerostomia.
It is noteworthy that, for patients who received surgery and adjuvant RT, the favorable impact of IMRT on feeding tube duration was not observed. Our analysis demonstrates no statistically significant difference in the rates of feeding tube placement or the duration of use for patients who underwent upfront surgery followed by RT. This suggests that the potential benefits of IMRT may be abrogated in patients who undergo surgery, at least with regard to feeding tube use. The reason for this may be the need to cover larger radiation portals in these patients, encompassing the entire operated region, with less opportunity to spare critical central structures.
Other notable findings of this analysis include the impact of chemotherapy and ethnicity on feeding tube rates and duration of use. Patients who receive concurrent chemotherapy have increased rates of feeding tube placement, but no statistically significant change in the duration of use, compared with those who do not receive chemotherapy. In addition, patients of black nonHispanic ethnicity also have increased rates of placement, but no increased durations, compared with other ethnic groups. Both of these findings may reflect underlying clinical practice patterns and assessment of risk; further evaluation on the impact of these trends is warranted.
This study does share the limitations of observational studies using claims data. Claims data are not collected for scientific purposes; hence, there may be issues with completion and accuracy. The data do not reflect patient or physician choices and recommendations. In addition, the linked SEER-Medicare database only includes patients aged 65 years; hence, younger patients and those with managed care are not included. The SEERMedicare linked database also does not include radiation target, radiation dose, or HPV status, all of which may significantly impact outcomes.
In addition to these general limitations, there are additional limitations that are specific to the current analysis. We used claims data to understand the placement and removal of feeding tubes based on procedure codes; nasogastric tubes, which are placed in the office, have not been captured. Similarly, ongoing feeding tube use is indicated by claims for feeding tube supplies; hence, patients who died with feeding tubes in place may be misallocated. In addition, rates of chronic feeding tube dependence underestimate the true burden of dysphagia after head and neck radiation, because they do not account for those individuals who elect to eat, albeit risking pneumonia and secondary complications, despite chronic dysphagia, stricture, or aspiration. Finally, previous studies have demonstrated improved cause-specific survival in patients who receive IMRT compared with 3DRT 24 ; consequently, patients who received 3DRT may have had early recurrences and never had the tube removed. If this is true, then the shorter duration of feeding tube use observed with IMRT may reflect fewer recurrences (and not improved functional recovery). In this analysis, we excluded patients who had a subsequent diagnosis of HNC in an attempt to eliminate this confounder; however, it is established that claims data are limited in the detection of recurrence. 40 In summary, the current analysis suggests that patients who received definitive IMRT had a statistically shorter duration of feeding tube use than those who received 3DRT. IMRT has been approved and widely accepted as a technique that reduces xerostomia and improves quality of life for patients with head and neck cancer. Our findings suggest that it may also have an impact on long-term swallowing function after treatment.
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